Optical imaging company NinePoint Medical has raised $34 million in a Series B funding round to help ongoing launch of a product that provides a better view of esophagul abnormalities.
Optical imaging company NinePoint Medical announced Thursday that it has raised $34 million in a Series B funding round.
The Cambirdge, Massachusetts company has developed the NvisionVLE Imaging System that allows physicians and pathologists to “endoscopically view, for the first time, real-time, high-resolution, cross sectional images of organs and tissues up to 3mm deep at better than 10 micron resolution,” the company news release said.
The investment comes from Corning Incorporate, which led the round, along with founding investors Third Rock Ventures and Prospect Venture Partners. A portion of the money will help to fund the ongoing commercial launch of the imaging system.
“The NvisionVLE Imaging System is an exciting new imaging technology that is enabling physicians to visualize esophageal abnormalities at and below the mucosal surface, helping inform clinical decision-making," said Charles S. Carignan, M.D., president and CEO of NinePoint Medical. "With new hospitals adopting the technology every month, and with the support of our investors and strategic guidance of our board, we can continue to expand our sales force to facilitate the adoption of NvisionVLE at more centers. Hospitals from New England, to Florida, to California are already offering this advanced imaging technology.
The technology was originally developed at Wellman Center for Photomedicine at The Massachusetts General Hospital from which NinePoint Medical licensed it.
Here's a video that shows how the NvisionVLE Imaging System works: